Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Gink­go part­ners up with Sen­si­ble Biotech­nolo­gies to forge mR­NA man­u­fac­tur­ing plat­form

Since the suc­cess­ful, glob­al re­lease of mR­NA-based Covid-19 vac­cines, the mR­NA plat­form has be­come a top fo­cus for bio­phar­ma com­pa­nies. Gink­go Bioworks’ lat­est part­ner­ship looks to fur­ther tap the mR­NA mar­ket.

On Mon­day, Sen­si­ble Biotech­nolo­gies — a Eu­ro­pean-based biotech look­ing to build a cell-based plat­form to pro­duce mR­NA — and Gink­go an­nounced a part­ner­ship to de­vel­op such a man­u­fac­tur­ing plat­form. The an­nounce­ment said most of the mR­NA that is used in vac­cines and oth­er ther­a­peu­tic prod­ucts is pro­duced by in vit­ro tran­scrip­tion, which is cell-free and us­es pu­ri­fied en­zymes. The stan­dard forms of mR­NA pro­duc­tion are lim­it­ed in how much can be made and need to go through cost­ly pu­rifi­ca­tion meth­ods to elim­i­nate byprod­ucts that could cause ad­verse re­ac­tions in pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.